Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China

被引:82
作者
Sun, Caijun [1 ,2 ]
Zhang, Yinfeng [1 ]
Feng, Liqiang [1 ]
Pan, Weiqi [1 ]
Zhang, Maochao [1 ]
Hong, Zheyu [1 ]
Ma, Xin [1 ]
Chen, Xiaoping [1 ]
Chen, Ling [1 ,2 ]
机构
[1] Chinese Acad Sci, GIBH, State Key Lab Resp Dis, Guangzhou 510530, Guangdong, Peoples R China
[2] Guangzhou Med Univ, Guangzhou Inst Resp Dis, Guangzhou 510120, Peoples R China
基金
中国国家自然科学基金;
关键词
Adenovirus; Antibody; AIDS; HIV; vaccine; HIV-1; VACCINE; IMMUNITY; GENE; STEP; REPLICATION; SEROTYPE-5; EXPANSION; TITERS;
D O I
10.1016/j.vaccine.2011.03.042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34% in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8%) and percentage (54.4%) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3837 / 3841
页数:5
相关论文
共 23 条
[1]
Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene:: Application in epidemiologic studies and in the design of adenovector vaccines [J].
Aste-Amézaga, M ;
Bett, AJ ;
Wang, FB ;
Casimiro, DR ;
Antonello, JM ;
Patel, DK ;
Dell, EC ;
Franlin, LL ;
Dougherty, NM ;
Bennett, PS ;
Perry, HC ;
Davies, ME ;
Shiver, JW ;
Keller, PM ;
Yeager, MD .
HUMAN GENE THERAPY, 2004, 15 (03) :293-304
[2]
Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 [J].
Benlahrech, Adel ;
Harris, Julian ;
Meiser, Andrea ;
Papagatsias, Timos ;
Hornig, Julia ;
Hayes, Peter ;
Lieber, Andre ;
Athanasopoulos, Takis ;
Bachy, Veronique ;
Csomor, Eszter ;
Daniels, Rod ;
Fisher, Kerry ;
Gotch, Frances ;
Seymour, Len ;
Logan, Karen ;
Barbagallo, Romina ;
Klavinskis, Linda ;
Dickson, George ;
Patterson, Steven .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (47) :19940-19945
[3]
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].
Buchbinder, Susan P. ;
Mehrotra, Devon V. ;
Duerr, Ann ;
Fitzgerald, Daniel W. ;
Mogg, Robin ;
Li, David ;
Gilbert, Peter B. ;
Lama, Javier R. ;
Marmor, Michael ;
del Rio, Carlos ;
McElrath, M. Juliana ;
Casimiro, Danilo R. ;
Gottesdiener, Keith M. ;
Chodakewitz, Jeffrey A. ;
Corey, Lawrence ;
Robertson, Michael N. .
LANCET, 2008, 372 (9653) :1881-1893
[4]
Aids research - Promising AIDS vaccine's failure leaves field reeling [J].
Cohen, Jon .
SCIENCE, 2007, 318 (5847) :28-29
[5]
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study [J].
Curlin, Marcel E. ;
Cassis-Ghavami, Farah ;
Magaret, Amalia S. ;
Spies, Gregory A. ;
Duerr, Ann ;
Celum, Connie L. ;
Sanchez, Jorge L. ;
Margolick, Joseph B. ;
Detels, Roger ;
McElrath, M. Juliana ;
Corey, Lawrence .
AIDS, 2011, 25 (02) :153-158
[6]
Adenoviral vectors for gene therapy [J].
Douglas, Joanne T. .
MOLECULAR BIOTECHNOLOGY, 2007, 36 (01) :71-80
[7]
Gahéry-Ségard H, 1998, J VIROL, V72, P2388
[8]
Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (Addl1520) for treatment of liver tumors [J].
Hong, SS ;
Habib, NA ;
Franqueville, L ;
Jensen, S ;
Boulanger, PA .
JOURNAL OF VIROLOGY, 2003, 77 (19) :10366-10375
[9]
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells [J].
Hutnick, Natalie A. ;
Carnathan, Diane G. ;
Dubey, Sheri A. ;
Cox, Kara S. ;
Kierstead, Lisa ;
Ratcliffe, Sarah J. ;
Robertson, Michael N. ;
Casimiro, Danilo R. ;
Ertl, Hildegund C. J. ;
Betts, Michael R. .
NATURE MEDICINE, 2009, 15 (08) :876-878
[10]
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector [J].
Kostense, S ;
Koudstaal, N ;
Sprangers, M ;
Weverling, GJ ;
Penders, G ;
Helmus, N ;
Vogels, R ;
Bakker, M ;
Berkhout, B ;
Havenga, M ;
Goudsmit, J .
AIDS, 2004, 18 (08) :1213-1216